SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), a $904 million market cap biotech company, executed stock sales amounting to $11,156, according to a recent SEC filing. The transactions, conducted under a pre-established Rule 10b5-1 trading plan, took place on January 10 and January 13, 2025. According to InvestingPro analysis, GYRE currently trades above its Fair Value, with a "Fair" overall financial health score.
On January 10, Ma sold 1,057 shares of common stock at a weighted average price of $10.02 per share, with individual transaction prices ranging from $10.00 to $10.38. Subsequently, on January 13, an additional 56 shares were sold at a weighted average price of $10.10 per share, with prices ranging from $10.00 to $10.20. The stock currently trades at $10.52, maintaining a strong liquidity position with a current ratio of 3.72.
Following these transactions, Ma holds 2,915,138 shares indirectly through a family member. The sales were part of a trading plan adopted on September 13, 2024, allowing for pre-scheduled transactions. While GYRE maintains a moderate debt level, InvestingPro subscribers can access additional insights about the company's financial health and valuation metrics.
In other recent news, Gyre Therapeutics has made significant changes to its leadership, appointing Ping Zhang as the lead independent director of its Board of Directors. Zhang, who possesses a robust financial background, will also serve on the Nominating and Corporate Governance Committee. Additionally, Gyre Therapeutics has reported changes at its indirectly owned subsidiary, Gyre Pharmaceuticals. Songjiang Ma has taken up the mantle as the new Chairman, following Ying Luo's decision to step down to focus on his role at GNI Group Ltd.
Zhang's extensive experience includes his current role as a Managing Partner at String Capital Management and previous positions at AEON Life Insurance (NS:LIFI) Company and Japan Asia Investment Co. His academic credentials comprise a B.S. from Fudan University and an M.B.A. from the University of Chicago Booth School of Business.
Gyre Therapeutics' subsidiary, Gyre Pharmaceuticals, is making strides in the People's Republic of China. It is conducting clinical trials for its drug F351 and commercializing ETUARY® (Pirfenidone capsule), a leading treatment for idiopathic pulmonary fibrosis. The company reported total revenues of $105.03 million in the last twelve months with a gross profit margin of 96.23%. These recent developments reflect Gyre Therapeutics' ongoing commitment to advancing its pipeline and leadership.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.